Q3 EPS Estimates for Journey Medical Reduced by Roth Capital

Journey Medical Co. (NASDAQ:DERM) – Analysts at Roth Capital cut their Q3 2025 EPS estimates for Journey Medical in a note issued to investors on Monday, November 4th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings per share of $0.20 for the quarter, down from their previous forecast of $0.24. The consensus estimate for Journey Medical’s current full-year earnings is ($1.04) per share. Roth Capital also issued estimates for Journey Medical’s Q4 2025 earnings at $0.32 EPS and FY2025 earnings at $0.43 EPS.

A number of other equities analysts also recently weighed in on the company. Rodman & Renshaw started coverage on Journey Medical in a report on Thursday, August 22nd. They issued a “buy” rating and a $9.00 target price on the stock. Lake Street Capital initiated coverage on shares of Journey Medical in a research note on Friday, September 6th. They issued a “buy” rating and a $9.00 price objective on the stock. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Journey Medical currently has an average rating of “Buy” and an average target price of $9.38.

Journey Medical Stock Up 3.0 %

NASDAQ:DERM opened at $5.44 on Wednesday. Journey Medical has a 1-year low of $2.85 and a 1-year high of $8.11. The firm has a market capitalization of $112.75 million, a price-to-earnings ratio of -272.00 and a beta of 0.92. The company has a current ratio of 1.36, a quick ratio of 1.08 and a debt-to-equity ratio of 1.75. The business’s fifty day moving average price is $5.54 and its 200 day moving average price is $4.96.

Journey Medical (NASDAQ:DERM) last announced its earnings results on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The firm had revenue of $14.86 million for the quarter, compared to analyst estimates of $13.81 million. Journey Medical had a net margin of 1.09% and a return on equity of 5.44%. During the same period last year, the firm earned ($0.46) earnings per share.

Institutional Trading of Journey Medical

Institutional investors have recently added to or reduced their stakes in the business. Nwam LLC bought a new position in shares of Journey Medical during the 1st quarter valued at $41,000. Acadian Asset Management LLC grew its position in shares of Journey Medical by 687.5% in the first quarter. Acadian Asset Management LLC now owns 222,663 shares of the company’s stock valued at $817,000 after purchasing an additional 194,389 shares during the last quarter. Heron Bay Capital Management bought a new position in shares of Journey Medical in the first quarter worth about $124,000. Rosalind Advisors Inc. acquired a new position in shares of Journey Medical during the 2nd quarter worth about $644,000. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in Journey Medical during the 2nd quarter valued at approximately $1,664,000. 7.25% of the stock is currently owned by institutional investors and hedge funds.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.